NCT03272464View on ClinicalTrials.gov

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

May 29, 2019

Primary Completion Date

July 24, 2019

Study Completion Date

December 27, 2019

Conditions
Melanoma
Interventions
DRUG

Trametinib

Trametinib may work by binding to your cancer cells to inhibit the cancer cells' signals to decrease cell growth.

DRUG

Dabrafenib

Dabrafenib may work by stopping your cancer cells from duplicating.

DRUG

INCB039110

Itacitinib may work by stopping your tumor cells from living and growing.

Trial Locations (1)

02214

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT03272464 - INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. | Biotech Hunter | Biotech Hunter